STAT+: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents
When it comes to a crucial controversy over pharmaceutical patents, the FDA has been MIA….
Category: Pharma
STAT+: Pharmalittle: We’re reading about Sanofi licensing Novavax’s Covid shot, Moderna’s RSV vaccine, and more
Hello there and happy Friday from STAT’s London outpost, where the weekend is mere hours…
The public wants Medicare to cover obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Yet another big financing round in immunology
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Takeda restructuring, Pfizer settling Zantac suits, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available
In the latest bid to widen access to medicines, a nonprofit is sending technology and…
STAT+: Pharmalittle: We’re reading about a boy dying in Pfizer trial; AstraZeneca yanking Covid shot, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
Pharma has over $500B in capital for deals
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Endo Health ordered to pay more than $1.5 billion in opioid criminal case
In the second-largest fine ever levied on a pharmaceutical company, Endo Health Solutions was ordered…
STAT+: Young boy dies in trial for Pfizer Duchenne gene therapy
A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular…
STAT+: Pharmalittle: We’re reading about MDMA for PTSD, a CRISPR treatment for blindness, and more
Top of the morning to you, and a fine one it is. There is nothing…
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck may have a competition for ever-scarce BCG
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about FTC reviewing Novo-Catalent deal, Amneal opioid settlement, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages and more
And so, another working week will soon draw to a close. Not a moment too…
ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Senate drug shortage bill would pay hospitals bonuses for good contracting practices
WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages…
STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious…
The biotech news you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: DEA reverses a policy to avert morphine shortages
WASHINGTON — The Drug Enforcement Agency is reversing a regulation that had been expected to…
The latest government crackdowns on biotech you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about FTC fighting ‘junk’ patents, Pfizer direct-to-consumer plans, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
.jpg)
STAT+: ‘Skinny labels’ on generic medicines saved Medicare $15 billion over a recent six-year period
A controversial provision of a federal law designed to speed copycat drugs to market and…
STAT+: FTC issues more warnings to drug companies for ‘junk’ patent listings
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it…
FDA wants to hear your thoughts on advisory committees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a Medicare price-negotiation ruling, pharma’s slipping reputation, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Pharma’s reputation with patient groups is sliding again thanks to prices and shortages
The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to…
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs…
STAT+: Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Vertex offers limited access to a cystic fibrosis drug in South Africa — and may undercut a court case
After months of sustained criticism, Vertex Pharmaceuticals reached an agreement to provide a pricey cystic…
STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Colombia issues a compulsory license for an HIV medicine and ‘plants a flag for global health equity’
After months of deliberation, the Colombian government has issued a compulsory license for an HIV…
STAT+: Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
Two years after biosimilars became available in the U.S., a higher proportion of patients using…
STAT+: Pharmalittle: We’re reading about Lilly buying a plant, a Pfizer antibiotic, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Pharmalittle: We’re reading about an OptumRx contract, 340B dispute resolution, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: New antibiotics were underprescribed for hard-to-treat infections, study finds
Although U.S. regulators approved several new antibiotics for combating hard-to-treat bacteria during a recent five-year…
STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Animal rights group urges SEC to investigate Charles River over monkey purchases
A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for…
STAT+: Pharmalittle: We’re reading about Lilly’s Zepbound for sleep apnea, the FDA budget, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share
The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment,…
STAT+: Pharmalittle: We’re reading about a J&J cough syrup, a Pfizer and Moderna patent suit, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
In response to controversy, a group of Colorado lawmakers is abandoning a bill that would…
What about the company Vertex didn’t buy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more
And so, another working week will soon draw to a close. Not a moment too…
Gas prices are hurting biotech
Want to stay on top of the science and politics driving biotech today? Sign up to get…